Ronit Satchi-Fainaro | Pharmacology | Outstanding Scientist Award

Posted on by ScienceFather

Prof Dr. Ronit Satchi-Fainaro | Pharmacology | Outstanding Scientist Award

 Cancer Biology Research Center at Tel Aviv University, Israel

Ronit Satchi-Fainaro is a prominent figure in cancer research, currently serving as a Full Professor in the Department of Physiology and Pharmacology at Tel Aviv University and Director of the Cancer Biology Research Center. With a Ph.D. in polymer chemistry and extensive postdoctoral training at renowned institutions, her research focuses on cancer biology, tumor dormancy, and the development of targeted nanomedicines. Satchi-Fainaro has pioneered multi-modality polymer therapeutics that combine anti-angiogenic agents with chemotherapeutics, significantly advancing the field of cancer treatment. Her impressive publication record includes groundbreaking articles in Nature Medicine and Cancer Cell, and she has filed multiple patents for her innovative findings. Additionally, she has received numerous accolades for her contributions to science, including the Humboldt Foundation Bessel Research Prize. Satchi-Fainaro’s leadership in interdisciplinary research and commitment to translating scientific discoveries into clinical applications make her a leading voice in modern cancer therapeutics.

Professional Profile

Education

Ronit Satchi-Fainaro has an impressive educational background that laid the foundation for her distinguished career in pharmacology and cancer research. She earned her Bachelor of Pharmacy (B.Pharm.) degree in Pharmacology from The Hebrew University, Faculty of Medicine, School of Pharmacy, in June 1995. Following her undergraduate studies, she completed an internship in Industrial Pharmacy at Perio Products Ltd. in Jerusalem in March 1996. Satchi-Fainaro then pursued her Ph.D. at the University of London, specializing in polymer chemistry, biochemistry, and cancer nanomedicine. Her doctoral research, titled “PDEPT: Polymer Directed Enzyme Prodrug Therapy,” was completed in November 1999 under the supervision of Prof. Ruth Duncan. Subsequently, she expanded her expertise through postdoctoral fellowships at Tel Aviv University and Harvard Medical School, focusing on tumor biology, molecular biology, and protein delivery, further solidifying her status as a leader in the field of cancer research and nanomedicine.

 

Professional Experience

Ronit Satchi-Fainaro is a distinguished Full Professor in the Department of Physiology and Pharmacology at Tel Aviv University and serves as the Director of the Cancer Biology Research Center. With over 15 years of leadership at the university, she has spearheaded a multidisciplinary research group focused on innovative cancer therapies. Satchi-Fainaro’s expertise encompasses polymer chemistry, biochemistry, and nanomedicine, leading to the development of targeted polymer therapeutics and nano-vaccines. She has collaborated with prominent institutions, including Harvard Medical School, where she contributed to significant advances in tumor biology and angiogenesis. Her entrepreneurial spirit is evident through her co-founding of biotech companies, such as ImmuNovation, Ltd., and her active role on various scientific advisory boards. Satchi-Fainaro has garnered numerous accolades, including the Humboldt Foundation Bessel Research Prize, reflecting her substantial impact in cancer research and drug delivery systems. Her work continues to push the boundaries of personalized medicine and cancer therapeutics

Research Interests

Ronit Satchi-Fainaro’s research interests lie at the intersection of cancer biology, pharmacology, and nanomedicine. She focuses on understanding the mechanisms underlying cancer dormancy and the tumor-host interactions that facilitate metastasis. Her innovative work involves developing targeted nanomedicines that integrate anti-stromal agents with chemotherapeutics to enhance treatment efficacy while reducing toxicity. Satchi-Fainaro’s laboratory employs advanced techniques such as molecular imaging, 3D bioprinted cancer models, and personalized theranostics to investigate tumor biology and angiogenesis. She aims to identify molecular signatures that predict tumor behavior and survivorship, driving the rational design of novel therapeutic approaches. Additionally, her interdisciplinary approach combines elements of biology, chemistry, engineering, and material sciences, facilitating the development of highly selective drug delivery systems. Through her pioneering research, Satchi-Fainaro aspires to contribute to more effective cancer therapies and improve patient outcomes in the fight against cancer.

Ronit Satchi-Fainaro has received numerous prestigious awards and honors throughout her distinguished career, reflecting her significant contributions to cancer research and nanomedicine. Notable accolades include the British Council Chevening Award, the Nagai Foundation Graduate Student Award, and the Fulbright Scholarship. She was recognized as a “Person of the Year” in Medicine by Forbes Israel and included in various influential lists, such as the “50 Most Influential Women” and “40 Under 40” by prominent Israeli journals. In addition, she has received the ERC Advanced Grant, the 3D Printing Industry Award for Medical Application of the Year, and the Bessel Research Prize from the Humboldt Foundation. Her work has garnered multiple research prizes for exceptional publications at Tel Aviv University and recognition as a Fellow of the American Institute of Medical and Biological Engineers (AIMBE). These accolades highlight her impactful research and leadership in advancing innovative cancer therapies.

 

Conclusion

Ronit Satchi-Fainaro is a distinguished leader in cancer research, whose innovative work in nanomedicine has significantly advanced the understanding and treatment of cancer. With a robust academic background and over 15 years at Tel Aviv University, she has successfully led multidisciplinary research initiatives that tackle complex questions in tumor biology and drug delivery. Her pioneering development of multi-modality targeted nanomedicines has not only garnered numerous patents but also positioned her at the forefront of translational research. Satchi-Fainaro’s impressive publication record in high-impact journals, coupled with her numerous accolades—including the Humboldt Foundation Bessel Research Prize—underscores her contributions to science. As the Director of the Cancer Biology Research Center, she exemplifies a commitment to fostering collaboration and mentorship in the scientific community. Overall, her accomplishments and dedication to improving cancer therapies make her a highly deserving candidate for the Research for Outstanding Scientist Award.

 

Publication top noted
  • Title: interFLOW: maximum flow framework for the identification of factors mediating the signaling convergence of multiple receptors
    Authors: Sheinin, R., Salomon, K., Yeini, E., Sharan, R., Madi, A.
    Year: 2024
    Citations: 0
  • Title: Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy
    Authors: Longobardi, G., Moore, T.L., Conte, C., Satchi-Fainaro, R., Quaglia, F.
    Year: 2024
    Citations: 0
  • Title: Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy
    Authors: Peres, C., Matos, A.I., Carreira, B., Satchi-Fainaro, R., Florindo, H.F.
    Year: 2024
    Citations: 2
  • Title: Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor Immunity
    Authors: Monteran, L., Ershaid, N., Scharff, Y., Zhang, X.H.-F., Erez, N.
    Year: 2024
    Citations: 3
  • Title: The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine
    Authors: Pozzi, S., Satchi-Fainaro, R.
    Year: 2024
    Citations: 3
  • Title: Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker
    Authors: Liubomirski, Y., Tiram, G., Scomparin, A., Shabat, D., Satchi-Fainaro, R.
    Year: 2024
    Citations: 3
  • Title: Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy
    Authors: Acúrcio, R.C., Kleiner, R., Vaskovich-Koubi, D., Florindo, H.F., Satchi-Fainaro, R.
    Year: 2024
    Citations: 0
  • Title: Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors
    Authors: Matos, A.I., Peres, C., Carreira, B., Satchi-Fainaro, R., Florindo, H.F.
    Year: 2023
    Citations: 6
  • Title: Deoxyhypusine hydroxylase: A novel therapeutic target differentially expressed in short-term vs long-term survivors of glioblastoma
    Authors: Ofek, P., Yeini, E., Arad, G., Geiger, T., Satchi-Fainaro, R.
    Year: 2023
    Citations: 4
  • Title: Development of Chitosan Particles Loaded with siRNA for Cystatin C to Control Intracellular Drug-Resistant Mycobacterium tuberculosis
    Authors: Pires, D., Mandal, M., Matos, A.I., Florindo, H.F., Anes, E.
    Year: 2023
    Citations: 6

Long Chen | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Long Chen | Pharmaceutical Science | Best Researcher Award

Assistant Professor, Peking University Third Hospital, China

Long Chen is a prominent researcher recognized for his impactful contributions in oncology and drug delivery systems. With 17 publications since 2015 and an impressive H-index of 39, his work has garnered 715 total citations, reflecting significant influence in the scientific community. His recent studies focus on critical challenges such as drug resistance in cancer therapies, showcasing his engagement with pressing medical issues. Chen’s research is characterized by a diverse range of innovative topics, enhancing the relevance of his work in contemporary science. While his individual contributions are substantial, fostering broader collaborations and increasing public engagement could further amplify his impact. Overall, Long Chen’s impressive publication record, high citation metrics, and dedication to advancing cancer research position him as a strong candidate for the Best Researcher Award, highlighting his potential for continued contributions to the field.

Profile:

Education

Long Chen obtained his Ph.D. in Biomedical Engineering from a prestigious institution, where he focused on advanced therapeutic strategies and drug delivery systems. His academic journey began with a Bachelor’s degree in Chemical Engineering, which laid a solid foundation in both theoretical and practical aspects of the field. Chen furthered his education with a Master’s degree in Pharmaceutical Sciences, enhancing his expertise in drug formulation and development. Throughout his studies, he engaged in various research projects, collaborating with multidisciplinary teams to explore innovative approaches in cancer therapy and nanomedicine. This strong educational background, coupled with hands-on research experience, has equipped Long Chen with the skills necessary to address complex challenges in biomedical research and significantly contribute to advancements in healthcare. His commitment to lifelong learning and continuous improvement is evident in his pursuit of knowledge across multiple domains within his field.

Professional Experience

Long Chen has accumulated significant professional experience in the field of biomedical research, focusing primarily on cancer therapy and drug delivery systems. He has held key research positions that emphasize his expertise in developing innovative therapeutic strategies and biomaterials. His recent work includes exploring the mechanisms of drug resistance in hepatocellular carcinoma and the design of protein-based nanoparticles for targeted cancer treatment. Chen has published extensively in high-impact journals, showcasing his findings and contributing to the scientific community’s understanding of complex biological processes. Additionally, he has been involved in collaborations that bridge basic research and clinical applications, enhancing the translational potential of his work. His role in various projects has not only solidified his reputation as a leading researcher but also allowed him to mentor emerging scientists in the field, further contributing to the growth of biomedical research and its applications in healthcare.

Research Skills

Long Chen possesses a diverse and robust set of research skills that have significantly contributed to his field. His expertise in drug synthesis and delivery is evident through his innovative work on nanomedicine and targeted therapeutics, which aims to improve cancer treatment efficacy. Proficient in advanced techniques such as protein engineering and bioorthogonal chemistry, he has successfully developed novel therapeutic platforms, including self-assembled nanoparticles and prodrug-antibody conjugates. His strong analytical skills are reflected in his ability to conduct rigorous experimental studies and publish in high-impact journals. Furthermore, Chen’s familiarity with computational modeling enhances his research by allowing for precise predictions of drug interactions and biological responses. With a solid foundation in interdisciplinary collaboration, he effectively integrates knowledge from chemistry, biology, and medicine, positioning himself as a leader in advancing therapeutic strategies against complex diseases. Overall, his research skills are critical to addressing pressing challenges in modern healthcare.

Award and Recognition

Long Chen has garnered significant recognition for his impactful contributions to cancer research and drug delivery systems. His innovative work has led to numerous publications in high-impact journals, reflecting his expertise in areas such as biomaterials and therapeutic development. Notably, his H-index of 39 indicates a substantial citation impact, underscoring the influence of his research within the scientific community. Additionally, Long’s work has been cited in various patents, demonstrating the practical applications of his findings in real-world scenarios. His recent publications address critical challenges in oncology, including drug resistance and targeted therapies, showcasing his commitment to advancing medical science. Long Chen’s achievements highlight his role as a leader in his field, making him a deserving candidate for prestigious awards that recognize excellence in research and innovation. His continued contributions promise to further enhance his reputation and impact in the scientific landscape.

Conclusion

In conclusion, Long Chen stands out as a prominent researcher deserving of the Best Researcher Award due to his impressive publication record and significant impact on the scientific community. With 17 publications in reputable journals and an H-index of 39, his work in areas such as cancer therapy and drug delivery systems highlights his expertise and relevance in contemporary research. The diversity of his topics, coupled with recent contributions addressing critical challenges like drug resistance, underscores his innovative approach. Furthermore, the citations from patents indicate the practical implications of his research, showcasing its applicability in real-world scenarios. By enhancing collaborations and engaging more with the public, Long Chen has the potential to further amplify his impact. Overall, his robust academic achievements and commitment to advancing knowledge make him a compelling candidate for this prestigious award.

Publication Top Notes

  • Title: Nanoalbumin–prodrug conjugates prepared via a thiolation‐and‐conjugation method improve cancer chemotherapy and immune checkpoint blockade therapy by promoting CD8+ T‐cell infiltration
    Authors: Long Chen, Nuo Xu, Pan Wang, Haichuan Zhu, Zijian Zhang, Zhanqun Yang, Wenyuan Zhang, Hongyan Guo, Jian Lin
    Journal: Bioengineering & Translational Medicine
    Year: 2023
    Citations: Not available yet
    DOI: 10.1002/btm2.10377
  • Title: LDL receptor-related protein 1 (LRP1), a novel target for opening the blood-labyrinth barrier (BLB)
    Authors: Xi Shi, Zihao Wang, Wei Ren, Long Chen, Cong Xu, Menghua Li, Shiyong Fan, Yuru Xu, Mengbing Chen, Fanjun Zheng et al.
    Journal: Signal Transduction and Targeted Therapy
    Year: 2022
    Citations: Not available yet
    DOI: 10.1038/s41392-022-00995-z
  • Title: Covalently Engineered Protein Minibinders with Enhanced Neutralization Efficacy against Escaping SARS-CoV-2 Variants
    Authors: Yu Han, Zhenlin Yang, Hengrui Hu, Heng Zhang, Long Chen, Kexin Li, Linghao Kong, Qianran Wang, Bo Liu, Manli Wang et al.
    Journal: Journal of the American Chemical Society
    Year: 2022
    Citations: Not available yet
    DOI: 10.1021/jacs.1c11554
  • Title: A Ferritin–Albumin–Cu Nanoparticle that Efficaciously Delivers Copper(II) Ions to a Tumor and Improves the Therapeutic Efficacy of Disulfiram
    Authors: Nuo Xu, Yuan-Fan Yang, Long Chen, Jian Lin
    Journal: ACS Omega
    Year: 2020
    Citations: Not available yet
    DOI: 10.1021/acsomega.0c00293
  • Title: Blood–Brain Barrier- and Blood–Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases
    Authors: Long Chen, Dan Zeng, Nuo Xu, Chengpeng Li, Wenyuan Zhang, Xinjie Zhu, Yan Gao, Peng R. Chen, Jian Lin
    Journal: ACS Applied Materials & Interfaces
    Year: 2019
    Citations: Not available yet
    DOI: 10.1021/acsami.9b14046

 

Kifayat Ullah Shah | Pharmaceutics | Best Researcher Award

Posted on by ScienceFather

Dr. Kifayat Ullah Shah | Pharmaceutics | Best Researcher Award

Associate Professor at Quaid-i-Azam University, Pakistan

Dr. Kifayat Ullah Shah is an accomplished academic and researcher in the field of pharmaceutical sciences, currently serving as an Associate Professor at Quaid-e-Azam University in Islamabad since September 2014. He previously held positions as an Assistant Professor at Hamdard University and a Teaching Assistant at Gomal University. Dr. Shah earned his Ph.D. in Pharmaceutics from Gomal University, where he also completed his Bachelor of Pharmacy. His research interests include the formulation and development of pharmaceuticals, controlled drug delivery, and nanotechnology applications in drug delivery. He has authored several publications with significant impact, reflecting his contributions to the field, and has supervised over 35 MPhil and five PhD students. Dr. Shah has received grants for various research projects, showcasing his commitment to advancing pharmaceutical sciences. Additionally, he is actively involved in academic administration and quality assurance within higher education.

Profile

Education

Dr. Kifayat Ullah Shah holds an impressive educational background in pharmaceutical sciences. He earned his Doctor of Philosophy (Ph.D.) in Pharmaceutics from Gomal University, Dera Ismāīl Khān, Khyber Pakhtunkhwa, Pakistan, between 2008 and 2014. Prior to that, he obtained a Bachelor of Pharmacy (B.Pharmacy) degree from the same institution, Gomal University, from 2002 to 2006. His early education includes a Pre-Medical F.Sc. from Govt. P.G. College Bannu in 2000-2001 and Matriculation in Science from Govt. High School-02 Bannu in 1998-1999. This strong academic foundation has equipped Dr. Shah with the knowledge and skills necessary to excel in both research and teaching within the field of pharmaceutical sciences.

Professional Experience

Dr. Kifayat Ullah Shah has extensive professional experience in academia and the pharmaceutical industry. He has served as an Associate Professor at Quaid-e-Azam University, Islamabad, since September 2014, where he has contributed to teaching and research in pharmaceutical sciences. Prior to this role, Dr. Shah was an Assistant Professor at Hamdard University from January to August 2014 and worked as a Teaching Assistant at Gomal University for a brief period in late 2011. His early career included experience as a Production Pharmacist at Glitz Pharmaceuticals in Islamabad, where he gained practical insights into pharmaceutical production and formulation. Dr. Shah’s diverse professional background, coupled with his research focus on drug delivery systems and nanotechnology, has positioned him as a prominent figure in his field.

Research Interest

Dr. Kifayat Ullah Shah’s research interests are centered around the formulation and development of pharmaceutical products, with a particular focus on controlled drug delivery systems. His expertise encompasses a variety of advanced techniques, including microencapsulation, nanotechnology, and thermal analysis, which he applies to improve the efficacy and safety of drug formulations. Dr. Shah has conducted significant research on targeted drug delivery mechanisms, exploring innovative methods to enhance therapeutic outcomes for various medical conditions. His work also includes the design, preparation, and evaluation of controlled release polymeric formulations, aiming to investigate drug release patterns and mechanisms. Through his research, Dr. Shah seeks to contribute to the advancement of pharmaceutical sciences and improve patient care through effective drug delivery systems.

Research Skills

Dr. Kifayat Ullah Shah possesses a robust skill set in pharmaceutical research, particularly in the formulation and development of drug delivery systems. His expertise includes advanced techniques such as microencapsulation, controlled drug delivery, and targeted drug delivery, which are essential for optimizing the therapeutic effects of pharmaceuticals. Dr. Shah is proficient in utilizing various analytical instruments, including UV/Visible spectrophotometry, differential scanning calorimetry (DSC), and thermal analysis, to evaluate and characterize pharmaceutical formulations. His research skills also extend to pre-formulation studies and the application of nanotechnology in drug delivery, enabling him to design innovative solutions for complex pharmaceutical challenges. Through his comprehensive knowledge and practical experience, Dr. Shah effectively contributes to the advancement of pharmaceutical sciences and the development of new therapeutic strategies.

Award and Recognition

Dr. Kifayat Ullah Shah has garnered several awards and recognitions throughout his career, highlighting his significant contributions to the field of pharmaceutics. He successfully obtained funding for key research projects, including a grant of 0.5 million PKR from the Higher Education Commission (HEC) of Pakistan for the fabrication, characterization, and in vitro evaluation of finasteride nanoparticles. Additionally, he received a substantial grant of 4.5 million PKR for his project on silica-based nanoparticles as hemostatic agents for controlling internal bleeding. Dr. Shah has also been recognized for his academic excellence, having supervised over 35 MPhil and five PhD students, and for his impactful research publications, which have contributed to advancements in drug delivery systems. His work has earned him respect and acknowledgment in the academic and research communities, reflecting his dedication to enhancing pharmaceutical sciences and improving patient care.

Conclusion

Dr. Kifayat Ullah Shah’s impressive academic credentials, extensive research experience, impactful publications, successful funding acquisitions, and contributions to education and administrative services strongly position him as a deserving candidate for the Research for Best Researcher Award. His ongoing commitment to advancing pharmaceutical sciences through research and mentorship further strengthens his suitability for this recognition.

Publication Top Notes

  • “Non-pharmacological management of hypertension: in the light of current research”
    • Journal: Irish Journal of Medical Science (1971-)
    • Cited by: 180
    • Year: 2019
    • Volume: 188
    • Pages: 437-452
  • “From nanoemulsions to self-nanoemulsions, with recent advances in self-nanoemulsifying drug delivery systems (SNEDDS)”
    • Journal: Expert Opinion on Drug Delivery
    • Cited by: 148
    • Year: 2017
    • Volume: 14, Issue 11
    • Pages: 1325-1340
  • “Proniosomes derived niosomes: recent advancements in drug delivery and targeting”
    • Journal: Drug Delivery
    • Cited by: 121
    • Year: 2017
    • Volume: 24, Issue 2
    • Pages: 56-69
  • “A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers”
    • Journal: Carbohydrate Polymers
    • Cited by: 106
    • Year: 2020
    • Volume: 250
    • Pages: 116800
  • “Elemental analysis of some medicinal plants used in traditional medicine by atomic absorption spectrophotometer (AAS)”
    • Journal: Journal of Medicinal Plants Research
    • Cited by: 93
    • Year: 2010
    • Volume: 4, Issue 19
    • Pages: 1987-1990
  • “Polymeric nanogels as versatile nanoplatforms for biomedical applications”
    • Journal: Journal of Nanomaterials
    • Cited by: 81
    • Year: 2019
    • Volume: 2019, Issue 1
    • Pages: 1526186
  • “Hemostatic strategies for uncontrolled bleeding: A comprehensive update”
    • Journal: Journal of Biomedical Materials Research Part B: Applied Biomaterials
    • Cited by: 73
    • Year: 2021
    • Volume: 109
  • “Development, in-vitro and in-vivo evaluation of ezetimibe-loaded solid lipid nanoparticles and their comparison with marketed product”
    • Journal: Journal of Drug Delivery Science and Technology
    • Cited by: 72
    • Year: 2019
    • Volume: 51
    • Pages: 583-590
  • “Prevalence of non-adherence to antihypertensive medication in Asia: a systematic review and meta-analysis”
    • Journal: International Journal of Clinical Pharmacy
    • Cited by: 56
    • Year: 2021
    • Volume: 43
    • Pages: 486-501
  • “Co-delivery strategies to overcome multidrug resistance in ovarian cancer”
    • Journal: International Journal of Pharmaceutics
    • Cited by: 47
    • Year: 2017
    • Volume: 533, Issue 1
    • Pages: 111-124
  • “Regulating drug release behavior and kinetics from matrix tablets based on fine particle‐sized ethyl cellulose ether derivatives: An in vitro and in vivo evaluation”
    • Journal: The Scientific World Journal
    • Cited by: 46
    • Year: 2012
    • Volume: 2012, Issue 1
    • Pages: 842348

 

 

Rashna Mirza | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Ms. Rashna Mirza | Pharmaceutical Science | Best Researcher Award

PhD scholar of Quaid-i-Azam University, Pakistan.

Rashna Mirza is a distinguished researcher currently pursuing a PhD at Quaid-i-Azam University, Islamabad, focusing on advanced drug delivery systems, including brain-targeted transfersomes and optimized nano-transfersomes. A Gold Medalist in Pharm D from People’s University of Medical and Health Sciences for Women, she has demonstrated exceptional academic and research prowess. Her professional experience includes roles in quality assurance, pharmaceutical research, and laboratory supervision, showcasing her expertise in drug formulation and optimization. Rashna’s commitment to the field is reflected in her impactful publications and active participation in conferences. Her strengths lie in cutting-edge research, scientific communication, and organizational skills, though expanding her research impact and gaining leadership experience could further enhance her profile. Rashna’s background and achievements make her a strong candidate for the Research for Best Researcher Award.

Profile

Education

Rashna Mirza’s educational background reflects her strong commitment to the field of pharmaceutics. She is currently pursuing a PhD at Quaid-i-Azam University, Islamabad, with research focused on advanced drug delivery systems, including brain targeting of Cefepime-loaded transfersomes and optimization of nano-transfersomes for transdermal delivery. Prior to her PhD, Rashna completed her M.Phil at the same institution, where she continued to build on her expertise in pharmaceutics. She earned her Pharm D from People’s University of Medical and Health Sciences for Women, where she graduated as a Gold Medalist, underscoring her exceptional academic performance. Rashna’s foundational education includes an FSC Pre-Medical from Government Girls Degree College, Islamabad, and matriculation from Foundation Public School, Karachi. This robust educational background has equipped her with a deep understanding of pharmaceutical sciences and a solid foundation for her research career.

Professional Experience

Rashna Mirza has a diverse professional background that underscores her expertise in pharmaceutics and drug development. Currently pursuing her PhD at Quaid-i-Azam University, she is engaged in pioneering research on brain-targeted drug delivery systems and transdermal gels. Her experience includes working as a Lab Demonstrator at Quaid-i-Azam University, where she managed laboratory work, supervised experiments, and facilitated instructional activities. She also served as a Quality Assurance Inspector at Herbiotics, where she conducted inspections, quality audits, and process monitoring. Additionally, Rashna worked as a Retail Pharmacist at Punjab Pharmacy, handling inventory management, patient counseling, and medication therapy management. Her academic journey is marked by her gold medal achievement in Pharm D from People’s University of Medical and Health Sciences for Women. Her professional roles reflect her strong organizational, supervisory, and research skills, contributing significantly to her field.

Research Interest

Rashna Mirza’s research interests center on the development and optimization of novel drug delivery systems to enhance therapeutic outcomes. Her current PhD research focuses on innovative approaches such as brain-targeting of Cefepime-loaded transfersomes and the formulation of nano-transfersomes-based chitosan gels for transdermal delivery. This work aims to improve drug efficacy and patient compliance through advanced delivery mechanisms. Rashna is also interested in the formulation and optimization of thermosensitive in situ gels, exploring their potential for controlled and targeted drug release. Her research integrates both in vitro and in vivo studies to address challenges in pharmaceutical science, emphasizing the importance of precise drug delivery for effective treatment. Rashna’s work is characterized by a commitment to advancing pharmaceutics through rigorous experimentation and collaboration, contributing valuable insights to the field and aiming to bridge gaps in current drug delivery technologies.

Research Skills

Rashna Mirza exhibits a strong suite of research skills that underscore her capabilities in advancing the field of pharmaceutics. Her expertise in drug formulation and optimization is evident through her current PhD research, which involves innovative drug delivery systems such as brain-targeting transfersomes and nano-transfersomes. Rashna’s proficiency in statistical design and optimization further enhances her ability to develop and refine novel drug delivery methods. Her hands-on laboratory skills are complemented by her experience in quality assurance and process monitoring, ensuring meticulous evaluation and control of research processes. Additionally, Rashna’s solid background in scientific communication and report writing enables her to effectively present and disseminate research findings. Her involvement in interdisciplinary collaboration and active participation in conferences reflects her commitment to integrating diverse perspectives and advancing scientific knowledge. Overall, Rashna’s research skills demonstrate a well-rounded and impactful approach to pharmaceutics and drug development.

Award and Recognition

Rashna Mirza, a distinguished researcher and Gold Medalist in Pharm D, has garnered significant recognition for her contributions to the field of pharmaceutics. Her innovative research on drug delivery systems, including brain-targeting transfersomes and nano-transfersome optimization, has been widely acknowledged within the scientific community. Rashna’s work is prominently featured in impactful publications, reflecting her dedication to advancing drug formulation and optimization. Her role as a Lab Demonstrator and Quality Assurance Inspector highlights her exceptional skills in scientific communication, process improvement, and interdisciplinary collaboration. Additionally, Rashna’s participation in notable conferences and her involvement in quality audits further underscore her commitment to excellence in pharmaceutical research. These achievements collectively affirm her as a leading figure in her field, earning her well-deserved recognition and positioning her as a promising candidate for prestigious awards in pharmaceutics and drug development.

Conclusion

Rashna Mirza’s strong background in pharmaceutics, demonstrated research capabilities, and commitment to advancing drug delivery systems position her as a suitable candidate for the Research for Best Researcher Award. Her strengths in innovative research, academic excellence, and effective communication support her candidacy, while opportunities for broader impact and leadership development could further enhance her profile.

Publication Top Notes

  • Brain targeting of cefepime loaded transfersomes based thermosensitive in situ gel via intranasal delivery: In vitro and in vivo studies
    • Authors: R. Mirza, A.U. Khan, K.U. Shah, F. Alasmari, Z. Hafeez
    • Year: 2024
    • Citations: 1
  • Statistical design and optimization of nano-transfersomes based chitosan gel for transdermal delivery of cefepime
    • Authors: R. Mirza, K.U. Shah, A.U. Khan, Z. Hafeez, S.U. Haq
    • Year: 2024

 

 

Bashige Chiribagula Valentin | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Bashige Chiribagula Valentin | Pharmaceutical Science | Best Researcher Award

Professor of UNILU, Congo.

Dr. Bashige Chiribagula Valentin is a prominent academic and researcher specializing in ethnopharmacology, medicinal chemistry, and quality control. Currently a professor at the University of Lubumbashi, he has held roles including department head, research specialist in pharmacognosy, and educator in pharmacology. His research focuses on the ethnobotanical, phytochemical, and pharmacological properties of medicinal plants, with significant contributions to the development of traditional medicine-based therapies, such as antimalarial and antimicrobial agents. Dr. Chiribagula has led various projects aimed at enhancing the quality and efficacy of herbal remedies and has published extensively in reputed journals. His work includes studies on plant-based treatments for malaria, diabetes, and wound healing, reflecting his commitment to integrating traditional knowledge with modern scientific approaches. His leadership in the academic and scientific community, coupled with his impactful research, underscores his candidacy for the Best Researcher Award.

Profile
Education

Dr. Bashige Chiribagula Valentin’s educational background is extensive and well-rounded. He earned his Doctorate in Pharmaceutical Sciences from the University of Lubumbashi (UNILU) and the Université de Mons (UMONS) in 2021, specializing in Pharmacognosy with a focus on ethnopharmacology. Prior to this, he obtained a Diplôme d’Études Approfondies in Pharmacognosy from UNILU in 2016. His foundational education includes a Diplôme de Pharmacie d’Industrie et Analyse de Médicaments from UNILU, completed in 2012, and a Diplôme d’Études Générales en Sciences Pharmaceutiques from the University of Kinshasa (UNIKIN) in 2006. His academic journey demonstrates a strong commitment to advancing knowledge in pharmaceutical sciences, particularly in the areas of pharmacognosy and ethnopharmacology.

Professional Experience

Dr. Bashige Chiribagula Valentin has an extensive and diverse professional background in the field of pharmacognosy and ethnopharmacology. He has served as a Professor at the University of Lubumbashi since 2022, where he also holds positions as President of juries and Secretary of the Department of Pharmacology. His career at the university began as an Assistant in 2013, progressing to a Chief of Works and Specialist in Pharmacognosy. In addition to his academic roles, Dr. Chiribagula has been actively involved in the pharmaceutical industry as a Quality Control Manager at PROMED Lubumbashi. His research focuses on ethnopharmacology, medicinal chemistry, and quality control of medicinal plants, contributing significantly to the development of traditional medicine projects. Dr. Chiribagula’s career also includes roles in secondary education and civil society, showcasing his dedication to both education and community service.

Research Interest

Dr. Bashige Chiribagula Valentin’s research focuses on the ethnopharmacological and medicinal properties of plants, particularly in the context of traditional medicine. His work spans the study of plant-based remedies for various diseases, including malaria and diabetes, with a strong emphasis on the pharmacognosy of medicinal plants. Dr. Chiribagula’s research integrates ethnobotanical surveys, phytochemical analysis, and pharmacological testing to explore and validate the therapeutic potential of natural substances. His projects include the development of medicinal plants for wound healing, anti-malarial, anti-ulcer, and antibacterial applications. Additionally, he investigates the nutritional and medicinal benefits of indigenous fungi, fruits, and vegetables. His research aims to bridge traditional knowledge with modern scientific validation, contributing to the development of effective, natural therapeutic agents and enhancing the quality of life in the Democratic Republic of Congo.

Research Skills

Dr. Bashige Chiribagula Valentin demonstrates a robust set of research skills essential for advancing his field of study. His expertise spans ethnopharmacology, medicinal chemistry, and quality control, with a strong emphasis on the pharmacognostic and phytochemical evaluation of medicinal plants. Dr. Chiribagula excels in employing various analytical techniques, including chromatography (TLC, Flash, HPLC), spectral analysis (MS), and microbiological assays (antimicrobial testing, antioxidant assays). His proficiency in using statistical software such as SPSS and GraphPad supports his rigorous data analysis. Additionally, he has a solid background in experimental design and execution, demonstrated by his work on traditional medicine and natural product research. His ability to integrate traditional knowledge with scientific methodologies underscores his contributions to the development of novel therapeutic agents and quality control measures in pharmaceuticals. Dr. Chiribagula’s comprehensive approach and methodological skills are integral to his research successes.

Awards and Recognition

Dr. Bashige Chiribagula Valentin has garnered significant recognition for his contributions to pharmacognosy and ethnopharmacology. He was honored as the “Major de Promotion” in 2012 and achieved notable accolades in 2019, securing first place at the MT180 regional AUF competition and second place at the national MT180 competition. His scholarly excellence is highlighted by his award-winning research on ethnobotanical studies and medicinal plants, which has been recognized in several prestigious journals. Dr. Chiribagula’s impactful work in the development of medicinal plant-based treatments, including those for malaria and wound healing, has further solidified his reputation in the scientific community. These awards underscore his dedication to advancing knowledge in pharmaceutical sciences and his commitment to improving public health through innovative research.

Conclusion

Bashige Chiribagula Valentin is a strong candidate for the Research for Best Researcher Award due to his substantial contributions to ethnopharmacology, his significant publications, and his active role in academia and the pharmaceutical industry. His expertise in traditional medicine and his impactful research on medicinal plants, coupled with his notable awards and professional experience, underline his qualifications for the award.

Publications Top Notes

  • Ethnomedical Knowledge of Plants Used in Nonconventional Medicine for Wound Healing in Lubumbashi, Haut‐Katanga Province, DR Congo
    • Authors: Bashige Chiribagula Valentin
    • Year: 2024
  • Ethnomedicinal Knowledge of Plants Used in Nonconventional Medicine in the Management of Diabetes Mellitus in Kinshasa (Democratic Republic of the Congo)
    • Authors: Bashige Chiribagula Valentin
    • Year: 2023
  • Ethnobotanical study of plants used by traditional healers in Lubumbashi (Democratic Republic of Congo) in the management of typhoid fever
    • Authors: Bashige Chiribagula Valentin
    • Year: 2022
  • Activité antioxydante de 53 plantes réputées antimalariques en République Démocratique du Congo
    • Authors: Bashige Chiribagula Valentin
    • Year: 2021
  • In vitro antioxidant activity and in vivo aphrodisiac activity in male Cavia porcellus of Albizia adianthifolia (Schum.) W. Wight and Pericopsis angolensis (Baker) Meeuwen
    • Authors: Bashige Chiribagula Valentin
    • Year: 2021
  • Knowledge, attitudes and practices among the population, towards COVID-19 in the Lubumbashi city (DR Congo): An online cross-sectional survey
    • Authors: Bashige Chiribagula Valentin
    • Year: 2021
  • Mineral elements analysis and total flavonoids content in the fresh leaves from two varieties of Hibiscus sabdariffa L. consumed as vegetable in Lubumbashi (DR Congo)
    • Authors: Bashige Chiribagula Valentin
    • Year: 2021
  • Antimicrobial, antioxidant activities and toxicity on Cavia porcellus of Dialium angolense Welw. Ex Oliv, a traditional medicinal plant from Bagira in Eastern of DR Congo
    • Authors: Bashige Chiribagula Valentin
    • Year: 2020
  • Ethnobotanical study of medicinal plants used in the treatment of sexual dysfunctions in traditional medicine in Kampemba-Lubumbashi, DR Congo
    • Authors: Bashige Chiribagula Valentin
    • Year: 2020
  • Antiplasmodial, antioxidant and toxicological study of leaves extracts of Dalbergia katangensis Lecheneaud (Fabaceae) from Eastern DR Congo
    • Authors: Bashige Chiribagula Valentin
    • Year: 2020

 

GHADEER SUAIFAN | Pharmaceutical Sciences | Best Researcher Award

Posted on by ScienceFather

Prof GHADEER SUAIFAN | Pharmaceutical Sciences | Best Researcher Award

Research Scholar, The University of Jordan, Jordan

Ghadeer A. Suaifan was born in December 1973 and is a Jordanian national. She is fluent in both Arabic and English. Ghadeer holds a PhD and an MPhil in Medicinal Chemistry and Instrumental Analysis from the University of Bath, UK, and a BSc (Honours) in Pharmacy from Petra University, Jordan. She currently serves as a Professor of Medicinal Chemistry and Pharmaceutical Instrumental Analysis at the Faculty of Pharmacy, The University of Jordan. Her research interests span medicinal chemistry, nanotechnology, and public health, with significant contributions in optimizing antidiabetic candidates, cancer treatments, and developing advanced analytical techniques. Ghadeer has published extensively and holds several patents.

Profile

Education🎓

From 2001 to 2004, Ghadeer A. Suaifan pursued a PhD in Medicinal Chemistry and Instrumental Analysis at the Department of Pharmacy and Pharmacology, University of Bath, UK. Prior to this, she completed an MPhil in Medicinal Chemistry and Instrumental Analysis at the same institution from 2000 to 2001. Ghadeer began her academic journey with a BSc (Honours) in Pharmacy from the College of Pharmacy, Petra University, Amman, Jordan, which she completed between 1991 and 1996. Her foundational education was acquired at Al-Room Al-Catholic School in Zarka, Jordan, where she earned her General Secondary Education Certificate from 1988 to 1991.

Experience 🏢

Prof. Ghadeer Suaifan is a distinguished Professor of Medicinal Chemistry and Pharmaceutical Instrumental Analysis at the Faculty of Pharmacy, The University of Jordan, where she has been serving since September 2016. In this role, she leads advanced research and teaching, significantly contributing to the academic and research excellence of the institution. Prior to this, she held the position of Associate Professor from September 2012 to September 2016, during which she focused on enhancing the curriculum and advancing research initiatives in medicinal chemistry and pharmaceutical sciences. From 2005 to 2012, Prof. Suaifan worked as an Assistant Professor at the same faculty, delivering undergraduate and postgraduate courses in pharmaceutical sciences and engaging in significant research activities. Additionally, she served as an Assistant Professor at the Faculty of Pharmacy, Philadelphia University, Amman, Jordan, from 2004 to 2005, where she contributed to the development of pharmaceutical education and research. Prof. Suaifan’s extensive experience and dedication have made her a vital asset to the field of pharmaceutical sciences in Jordan.

Research Interests 🔬

Ghadeer’s research encompasses Medicinal Chemistry and Instrumental Analysis, focusing on optimizing new antidiabetic candidates, elucidating molecular structures, and developing advanced prodrug systems for prostate cancer. Her work extends to Nanotechnology, including biological particle detection, miniaturized instrumentation, and medical diagnostics. She also investigates Public Research, evaluating antibiotic use behaviors and the prevalence of Complementary and Alternative Medicine in Jordan.

Special Awards 🏆

Professor Ghadeer Suaifan has been recognized for her outstanding contributions to research and development. She received the prestigious Ibtikar Award from Mewiin, Kuwait, in 2020. Her dedication to scientific research was further acknowledged with the Samia Mango Award from the Hamdi Mango Center for Scientific Research in Amman, Jordan, in 2018. In 2015, she was honored with the Excellent Oral Presenter Award at the International Conference on Pharmaceutical Sciences (ICPS) held in Dubai. Professor Suaifan’s academic achievements were consistently recognized during her time at the Faculty of Pharmacy, Petra University, where she received University Awards for Best Achievement from 1991 to 1996. In addition to her accolades, she has been a Registered Pharmacist with the Jordanian Pharmacists Association in Amman since January 1996, showcasing her longstanding commitment to the pharmaceutical profession and her continuous contributions to the field.

Publications Top Notes 📚

  1. Magnetic beads-based nanozyme for portable colorimetric biosensing of Helicobacter pylori
    • Authors: Suaifan, G.A.R.Y., Shehadeh, M.B., Darwish, R.M., Alaridah, N., Zourob, M.
    • Year: 2024
    • Journal: Biosensors and Bioelectronics: X, Volume 20, Article 100517
  2. Rapid Colorimetric Quantitative Portable Platform for Detection of Brucella melitensis Based on a Fluorescence Resonance Energy Transfer Assay and Nanomagnetic Particles
    • Authors: Alhogail, S., Chinnappan, R., Suaifan, G.A., Jürgen, P., Zourob, M.M.
    • Year: 2024
    • Journal: ACS Omega, Volume 9, Issue 19, Pages 20997–21005
  3. A cross-sectional study on adult lifestyle habits during the COVID-19 pandemic
    • Authors: Suaifan, G.A.R.Y., Abu-Odeh, A.M., Shehadeh, M.B., Jbara, W.A., Nassar, R.I.
    • Year: 2024
    • Journal: PLoS ONE, Volume 19, Issue 5, Article e0299668
  4. Synthesis, urease inhibitory and anticancer evaluation of glucosamine-sulfonylurea conjugates
    • Authors: Suaifan, G.A.R.Y., Shehadeh, M., Tahboub, D., Gaurav, A., Khan, M.
    • Year: 2024
    • Journal: Medicinal Chemistry Research, Volume 33, Issue 4, Pages 663–676
  5. Glucosamine substituted sulfonylureas: IRS-PI3K-PKC-AKT-GLUT4 insulin signalling pathway intriguing agent
    • Authors: Suaifan, G.A.R.Y., Alkhawaja, B., Shehadeh, M.B., Hor Kuan, C., Okechukwu, P.N.
    • Year: 2024
    • Journal: RSC Medicinal Chemistry, Volume 15, Issue 2, Pages 695–703
  6. Development of Rapid Aptamer-Based Screening Assay for the Detection of Covid-19 Variants
    • Authors: Aloraij, Y.M., Suaifan, G.A.R.Y., Shibl, A., Al-Kattan, K., Zourob, M.M.
    • Year: 2023
    • Journal: ACS Omega, Volume 8, Issue 36, Pages 32877–32883
  7. Medicinal plants of Jordan: Scoping review
    • Authors: Abu-Odeh, A., Fino, L., Al-Absi, G., Shehadeh, M., Suaifan, G.
    • Year: 2023
    • Journal: Heliyon, Volume 9, Issue 6, Article e17081
  8. Antibiotic—Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapy
    • Authors: Suaifan, G.A.R.Y., Abdel Rahman, D.M.A., Abu-Odeh, A.M., Shehadeh, M.B., Darwish, R.M.
    • Year: 2023
    • Journal: PLoS ONE, Volume 18, Issue 3, Article e0282705
  9. Knowledge, practice and attitude associated with SARS-CoV-2 Delta Variant among adults in Jordan
    • Authors: Suaifan, G.A.R.Y., Abu-Odeh, A.M., Shehadeh, M.B., Shahwan, M., Jbara, F.A.
    • Year: 2022
    • Journal: PLoS ONE, Volume 17, Issue 12, Article e0278243

 

 

Taigang Liang | Drug Design | Best Researcher Award

Posted on by ScienceFather

Prof. Taigang Liang | Drug Design | Best Researcher Award

Professor at School of Pharmacy/Shanxi Medical University, China.

Prof. Tai Gang Liang excels in drug synthesis, focusing on developing novel pharmaceutical compounds. His research spans drug action mechanisms, where he explores how drugs interact with biological systems to produce therapeutic effects. Liang is skilled in computer-aided drug design, using computational tools to optimize drug candidates efficiently. He also integrates Traditional Chinese Medicine (TCM) with modern scientific methods to advance drug development and industrialization. His expertise extends to biological evaluation techniques, sustainable synthesis, and analytical methods, ensuring comprehensive assessments of drug efficacy and safety. Prof. Liang’s innovative approaches contribute significantly to enhancing drug discovery and development processes. 🧪🔬💻

Professional Profiles:

Education

Prof. Tai Gang Liang, a distinguished scientist at Shanxi Medical University’s School of Pharmacy, has a robust educational background in pharmaceutical sciences. He earned his Doctor of Philosophy (PhD) in 2011, Master of Science (MS) in 2003, and Bachelor of Science (BS) in 2000, all from Shanxi Medical University. His extensive expertise spans drug synthesis, drug action mechanisms, computer-aided drug design, and the industrialization of traditional Chinese medicine (TCM). Prof. Liang’s research is recognized for its contributions to both the development of novel drug compounds and innovative drug design methodologies. His academic journey reflects a deep commitment to advancing pharmaceutical sciences and addressing global health challenges through cutting-edge research.

Professional Experience

Prof. Tai Gang Liang is a distinguished scientist at the School of Pharmacy, Shanxi Medical University, with extensive expertise in drug synthesis, drug action mechanisms, and computer-aided drug design. His research also focuses on the industrialization of traditional Chinese medicine (TCM). Over his career, Prof. Liang has received several prestigious awards, including being named a Shanxi Province Outstanding Young Scholar and a member of the Shanxi Province “131 Leading Talent Engineering.” He also earned the Silver Prize at the 12th “Challenge Cup” China College Entrepreneurship Plan Competition. His work has made significant contributions to advancing pharmaceutical sciences and TCM research, reflecting his dedication to innovation and excellence in the field.

 Research Interest

Prof. Tai Gang Liang’s research interests encompass a broad spectrum within pharmaceutical sciences. His primary focus includes drug synthesis and drug action mechanisms, where he aims to develop novel therapeutic agents and understand their biological effects. He is also deeply involved in computer-aided drug design, utilizing computational tools to optimize drug development processes. Additionally, Prof. Liang investigates the industrialization of traditional Chinese medicine (TCM), striving to integrate traditional practices with modern scientific techniques to enhance the efficacy and application of TCM therapies. His research aims to bridge the gap between traditional and modern medicinal approaches, advancing both fields through innovative solutions and interdisciplinary collaboration.

Award and Honors

Prof. Tai Gang Liang has received several notable awards and honors in recognition of his contributions to the field of pharmaceutical sciences. He was named a Shanxi Province Outstanding Young Scholar, highlighting his exceptional achievements and potential in his research domain. He is also a member of the Shanxi Province “131 Leading Talent Engineering”, an accolade given to influential professionals in the province. Additionally, Prof. Liang was awarded the Silver Prize at the 12th “Challenge Cup” China College Entrepreneurship Plan Competition, reflecting his innovative approach and entrepreneurial spirit in scientific endeavors. These accolades underscore his dedication and significant impact in drug development and traditional Chinese medicine. 🏆🌟

 Research Skills

Prof. Tai Gang Liang excels in drug synthesis, focusing on developing novel pharmaceutical compounds. His research spans drug action mechanisms, where he explores how drugs interact with biological systems to produce therapeutic effects. Liang is skilled in computer-aided drug design, using computational tools to optimize drug candidates efficiently. He also integrates Traditional Chinese Medicine (TCM) with modern scientific methods to advance drug development and industrialization. His expertise extends to biological evaluation techniques, sustainable synthesis, and analytical methods, ensuring comprehensive assessments of drug efficacy and safety. Prof. Liang’s innovative approaches contribute significantly to enhancing drug discovery and development processes. 🧪🔬💻

Publications
  1. Green synthesis of selenium nanoparticles with extract of hawthorn fruit induced HepG2 cells apoptosis
    • Authors: D Cui, T Liang, L Sun, L Meng, C Yang, L Wang, T Liang, Q Li
    • Year: 2018
    • Citations: 112
  2. Comparison of the Phenolic Content and Antioxidant Activities of Apocynum venetum L. (Luo-Bu-Ma) and Two of Its Alternative Species
    • Authors: T Liang, W Yue, Q Li
    • Year: 2010
    • Citations: 107
  3. Selenium nanoparticles fabricated in laminarin polysaccharides solutions exert their cytotoxicities in HepG2 cells by inhibiting autophagy and promoting apoptosis
    • Authors: D Cui, J Ma, T Liang, L Sun, L Meng, T Liang, Q Li
    • Year: 2019
    • Citations: 93
  4. Synthesis, characterization and antitumor properties of selenium nanoparticles coupling with ferulic acid
    • Authors: D Cui, C Yan, J Miao, X Zhang, J Chen, L Sun, L Meng, T Liang, Q Li
    • Year: 2018
    • Citations: 78
  5. Chemopreventive Effects of Peucedanum praeruptorum DUNN and Its Major Constituents on SGC7901 Gastric Cancer Cells
    • Authors: T Liang, W Yue, Q Li
    • Year: 2010
    • Citations: 51
  6. Farrerol Directly Targets GSK‐3β to Activate Nrf2‐ARE Pathway and Protect EA.hy926 Cells against Oxidative Stress‐Induced Injuries
    • Authors: C Yan, X Zhang, J Miao, H Yuan, E Liu, T Liang, Q Li
    • Year: 2020
    • Citations: 37
  7. Apoptosis induced by farrerol in human gastric cancer SGC-7901 cells through the mitochondrial-mediated pathway
    • Authors: E Liu, T Liang, X Wang, S Ban, L Han, Q Li
    • Year: 2015
    • Citations: 35
  8. Diorganotin (IV) complexes with 4-nitro-N-phthaloyl-glycine: Synthesis, characterization, antitumor activity and DNA-binding studies
    • Authors: C Yan, J Zhang, T Liang, Q Li
    • Year: 2015
    • Citations: 35
  9. Relaxation of rat aorta by farrerol correlates with potency to reduce intracellular calcium of VSMCs
    • Authors: X Qin, X Hou, M Zhang, T Liang, J Zhi, L Han, Q Li
    • Year: 2014
    • Citations: 31
  10. Sustained ERK activation-mediated proliferation inhibition of farrerol on human gastric carcinoma cell line by G0/G1-phase cell-cycle arrest
    • Authors: E Liu, J Li, S Shi, X Wang, T Liang, B Wu, Q Li
    • Year: 2016
    • Citations: 26

 

Giovanna Rassu | Toxicology and Pharmaceutical Science | Women Researcher Award

Posted on by ScienceFather

Assoc Prof Dr. Giovanna Rassu | Toxicology and Pharmaceutical Science | Women Researcher Award

Associate Professor at University of Sassari, Italy.

Dr. Giovanna Rassu is an accomplished Associate Professor in Pharmaceutical Technology with over 10 years of academic experience. She holds a Ph.D. in Pharmaceutical, Food, and Cosmetic Sciences and has undergone specialized training in biotechnology and pharmaceutical development. Throughout her career, Dr. Rassu has conducted extensive research focused on designing and characterizing novel drug delivery systems for the treatment of various diseases, including cancer and neurodegenerative disorders. Her expertise encompasses in-vitro and ex-vivo characterization techniques, and she has a strong publication record with numerous citations. Dr. Rassu is an active participant in academic conferences and workshops, where she shares her insights on drug delivery advancements. Additionally, she serves as an editorial board member and reviewer for several scientific journals and holds memberships in prestigious professional organizations. Dr. Rassu’s contributions to the field of pharmaceutical technology have been recognized with awards, including the “Women in Nanoscience Award.” Overall, her dedication to research, teaching, and academic leadership underscores her significant impact on advancing pharmaceutical sciences.

Professional Profiles:

Education

Associate Professor Dr. Giovanna Rassu boasts a rich educational background, culminating in a Ph.D. in Pharmaceutical, Food, and Cosmetic Sciences from the University of Genoa, which she completed between January 2004 and December 2006. Her doctoral journey concluded on April 20, 2007, marking a significant milestone in her academic career. Prior to this, she pursued a Master II Level program in Pre-formulation, Pharmaceutical Development, and Drug Control at the University of Pavia from March 2008 to October 2008, earning her diploma on October 22, 2008. Additionally, Dr. Rassu completed a Training Course of Technologies Applied to Biotechnology at Porto Conte Ricerche, Alghero, Italy, from September 2009 to January 2010. Her educational journey began with a Master’s Degree in Pharmaceutical Chemistry and Technology at the University of Sassari, where she graduated with distinction, scoring 110/110 with praise, from October 1997 to March 2003. She commenced her academic pursuits with a High School Diploma from the National teacher’s college “Margherita di Castelvì”, Sassari, where she excelled with a perfect score of 60/60 from September 1992 to June 1997. Through these educational endeavors, Dr. Rassu laid a solid foundation for her subsequent achievements and contributions in the field of pharmaceutical technology.

Professional Experience

Dr. Giovanna Rassu has amassed a wealth of professional experience in the pharmaceutical field, spanning both academic and research roles. Since November 1st, 2018, she has served as an Associate Professor in Pharmaceutical Technology at the Department of Medical, Surgical, and Experimental Sciences at the University of Sassari. Prior to this, from May 16th, 2011, to October 3rd, 2018, Dr. Rassu held the position of Researcher in Pharmaceutical Technology at the Department of Chemistry and Pharmacy, also at the University of Sassari. Her academic journey began as a Research Fellow at the Department of Pharmaceutical Sciences of the University of Sassari, where she contributed to the development of research projects funded by Banco di Sardegna Bank from July 1st, 2009, to May 15th, 2011, and from May 2nd, 2007, to May 2nd, 2009. Throughout her tenure, Dr. Rassu has exhibited dedication and expertise, making significant contributions to the advancement of pharmaceutical technology and drug delivery systems.

Research Interest

Dr. Giovanna Rassu’s research interests primarily focus on the design, preparation, and characterization of novel drug delivery systems for various routes of administration. Specifically, she is interested in developing drug delivery systems intended for the treatment of diseases such as cancer and neurodegenerative disorders. Her research endeavors also encompass the in-vitro and ex-vivo characterization of these delivery systems, with a particular emphasis on nasal formulations for systemic administration and brain targeting of therapeutics. Through her work, Dr. Rassu aims to advance the field of pharmaceutical technology and contribute to the development of more effective and targeted drug delivery strategies.

Award and Honors

Dr. Giovanna Rassu has been recognized for her exemplary contributions to the field of nanoscience, receiving the prestigious “WOMEN IN NANOSCIENCE AWARD” at the Global Conference on Nanotechnology. This award underscores her significant achievements and leadership in advancing research and innovation within the nanoscience community. It highlights her dedication and impact in pushing the boundaries of knowledge and fostering advancements in drug delivery and pharmaceutical technology.

Research Skills

Dr. Giovanna Rassu possesses a diverse range of research skills that have contributed to her success in the field of pharmaceutical technology. Her expertise includes the design, preparation, and characterization of novel drug delivery systems for various routes of administration, with a focus on treating diseases such as cancer and neurodegenerative disorders. She is proficient in in-vitro and ex-vivo characterization techniques, allowing for thorough assessment of drug delivery system performance. Additionally, Dr. Rassu demonstrates strong analytical skills in interpreting research data and drawing meaningful conclusions. Her research skills are complemented by her ability to collaborate effectively with multidisciplinary teams and her commitment to staying updated with the latest advancements in the field.

Publications

  1. Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies
    • Authors: E Gavini, AB Hegge, G Rassu, V Sanna, C Testa, G Pirisino, J Karlsen, …
    • Year: 2006
    • Citations: 239
  2. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy
    • Authors: G Rassu, E Soddu, AM Posadino, G Pintus, B Sarmento, P Giunchedi, …
    • Year: 2017
    • Citations: 194
  3. Nanoemulsions for “nose-to-brain” drug delivery
    • Authors: MC Bonferoni, S Rossi, G Sandri, F Ferrari, E Gavini, G Rassu, …
    • Year: 2019
    • Citations: 187
  4. Indocyanine green delivery systems for tumour detection and treatments
    • Authors: EP Porcu, A Salis, E Gavini, G Rassu, M Maestri, P Giunchedi
    • Year: 2016
    • Citations: 161
  5. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in-vitro characterization, ex-vivo and in-vivo studies
    • Authors: V Sanna, E Gavini, M Cossu, G Rassu, P Giunchedi
    • Year: 2007
    • Citations: 146
  6. Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclopramide: in-vitro/ex-vivo studies
    • Authors: E Gavini, G Rassu, V Sanna, M Cossu, P Giunchedi
    • Year: 2005
    • Citations: 144
  7. Solid microparticles based on chitosan or methyl-β-cyclodextrin: A first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate
    • Authors: G Rassu, E Soddu, M Cossu, A Brundu, G Cerri, N Marchetti, L Ferraro, …
    • Year: 2015
    • Citations: 140
  8. Spray-dried microspheres based on methylpyrrolidinone chitosan as new carrier for nasal administration of metoclopramide
    • Authors: E Gavini, G Rassu, C Muzzarelli, M Cossu, P Giunchedi
    • Year: 2008
    • Citations: 125
  9. Composite chitosan/alginate hydrogel for controlled release of deferoxamine: A system to potentially treat iron dysregulation diseases
    • Authors: G Rassu, A Salis, EP Porcu, P Giunchedi, M Roldo, E Gavini
    • Year: 2016
    • Citations: 107
  10. Preparation, In Vitro Characterization and Preliminary In Vivo Evaluation of Buccal Polymeric Films Containing Chlorhexidine
    • Authors: C Juliano, M Cossu, P Pigozzi, G Rassu, P Giunchedi
    • Year: 2008
    • Citations: 98